Company Performance - Aligos Therapeutics reported a quarterly loss of 2.15, representing an earnings surprise of -42.79% [1] - The company posted revenues of 2.15 million in the same quarter last year [2] - Over the last four quarters, Aligos has surpassed consensus EPS estimates two times and topped revenue estimates just once [2] Stock Performance - Aligos Therapeutics shares have declined approximately 40.8% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current Zacks Rank for Aligos is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -1 million in revenues, and for the current fiscal year, it is -2.6 million in revenues [7] - The outlook for the Medical - Biomedical and Genetics industry is relatively strong, ranking in the top 38% of over 250 Zacks industries, suggesting potential for better performance compared to lower-ranked industries [8]
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates